Investors may be wary of buying a stock that is hitting new all-time highs, but history has shown us that this is a sign of strength and higher highs are likely ahead. The trend is our friend in this market, and the two biopharmaceutical stocks we will delve into below are trending exceptionally well.
As investors we want to be in leading stocks. The problem for most investors is that they fail to notice the relevant signs and distinctions from the leaders. They are too busy holding on to former losers hoping to break even, and refuse to recognize the ‘buy’ signals that leading stocks are demonstrating under the surface. These investors often pay too much attention to the financial news media, who are usually wrong and don’t normally invest in the stocks they tout on TV.
The best investors exhibit great discipline and employ a method that has a history of outperformance. They are extremely patient and wait for proper entry points. They know what to look for in terms of price patterns, sector rotation, and relative strength. These investors have built a process that enables them to identify leading stocks at any given point in time.
Here at Zacks we give you the tools to help identify these leading stocks and outperform the market. Our Zacks Industry Rank identifies the top industry groups that contain market leaders, providing a tailwind to your investing success. Our Zacks Rank methodology pinpoints stocks that are witnessing positive earnings estimate revision activity, allowing investors to jump on board before an emerging rally gets underway. And our Earnings ESP filter empowers investors by allowing them the opportunity to detect stocks that are most likely to beat consensus estimates.
These are just a select few of the benefits available to Zacks’ subscribers. Our Zacks Style Scores and Premium Screeners also assist investors in narrowing down the investable universe to only the top names. That’s the key – we only want to include the best of the best in our portfolio, which will allow us to maximize our investing potential.
Let’s discuss two biopharmaceutical stocks that are displaying recent relative strength and are trending well this year. These stocks have led the major indexes and are showing signs of continued outperformance.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report)
Regeneron Pharmaceuticals is a biopharmaceutical company that invents, develops, manufactures and commercializes therapeutic medicines for the treatment of severe medical conditions. REGN has developed therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma. Founded in 1988 and headquartered in Tarrytown, NY, REGN has established collaboration and license agreements with companies such as Sanofi, Bayer, Roche Pharmaceuticals, as well as an agreement with the U.S. Department of Health and Human Services.
REGN’s key growth driver is Eylea, its treatment for neovascular age-related macular degeneration as well as diabetic macular edema. Growth in the U.S. markets is being driven by demographic trends with an aging population and an overall increase in the prevalence of diabetes. REGN has seen an incremental contribution from its REGEN-COV virus treatment which has boosted revenues significantly. We expect sales to continue their recent trend as the pandemic lingers on.
Trading at an undervalued 15.99 forward P/E relative to its industry (23.75), Regeneron has surpassed earnings estimates in each of the past five quarters. The company has delivered a trailing four-quarter average earnings surprise of +32.36%. REGN most recently announced Q4 EPS back in February of $23.72, a +28.29% surprise over estimates. The stock has risen in tune with these earnings beats, advancing nearly 50% in the past year.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Investors may be wary of buying a stock that is hitting new all-time highs, but history has shown us that this is a sign of strength and higher highs are likely ahead. The trend is our friend in this market, and the two biopharmaceutical stocks we will delve into below are trending exceptionally well.
As investors we want to be in leading stocks. The problem for most investors is that they fail to notice the relevant signs and distinctions from the leaders. They are too busy holding on to former losers hoping to break even, and refuse to recognize the ‘buy’ signals that leading stocks are demonstrating under the surface. These investors often pay too much attention to the financial news media, who are usually wrong and don’t normally invest in the stocks they tout on TV.
The best investors exhibit great discipline and employ a method that has a history of outperformance. They are extremely patient and wait for proper entry points. They know what to look for in terms of price patterns, sector rotation, and relative strength. These investors have built a process that enables them to identify leading stocks at any given point in time.
Here at Zacks we give you the tools to help identify these leading stocks and outperform the market. Our Zacks Industry Rank identifies the top industry groups that contain market leaders, providing a tailwind to your investing success. Our Zacks Rank methodology pinpoints stocks that are witnessing positive earnings estimate revision activity, allowing investors to jump on board before an emerging rally gets underway. And our Earnings ESP filter empowers investors by allowing them the opportunity to detect stocks that are most likely to beat consensus estimates.
These are just a select few of the benefits available to Zacks’ subscribers. Our Zacks Style Scores and Premium Screeners also assist investors in narrowing down the investable universe to only the top names. That’s the key – we only want to include the best of the best in our portfolio, which will allow us to maximize our investing potential.
Let’s discuss two biopharmaceutical stocks that are displaying recent relative strength and are trending well this year. These stocks have led the major indexes and are showing signs of continued outperformance.
Regeneron Pharmaceuticals, Inc. (REGN - Free Report)
Regeneron Pharmaceuticals is a biopharmaceutical company that invents, develops, manufactures and commercializes therapeutic medicines for the treatment of severe medical conditions. REGN has developed therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma. Founded in 1988 and headquartered in Tarrytown, NY, REGN has established collaboration and license agreements with companies such as Sanofi, Bayer, Roche Pharmaceuticals, as well as an agreement with the U.S. Department of Health and Human Services.
REGN’s key growth driver is Eylea, its treatment for neovascular age-related macular degeneration as well as diabetic macular edema. Growth in the U.S. markets is being driven by demographic trends with an aging population and an overall increase in the prevalence of diabetes. REGN has seen an incremental contribution from its REGEN-COV virus treatment which has boosted revenues significantly. We expect sales to continue their recent trend as the pandemic lingers on.
Trading at an undervalued 15.99 forward P/E relative to its industry (23.75), Regeneron has surpassed earnings estimates in each of the past five quarters. The company has delivered a trailing four-quarter average earnings surprise of +32.36%. REGN most recently announced Q4 EPS back in February of $23.72, a +28.29% surprise over estimates. The stock has risen in tune with these earnings beats, advancing nearly 50% in the past year.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.2% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>
Get the latest research report on REGN - FREE
Get the latest research report on BMY - FREE